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Some 10 years ago it emerged that at sufficiently high concentrations certain monoclonal
mouse IgEs exert previously unsuspected effects on mast cells. Thus they can both pro-
mote survival and induce activation of mast cells without the requirement for antigens.
This was a wake up call that appears to have been missed (or dismissed) by the majority
of immunologists. The structural attributes responsible for the potency of the so-called
“highly cytokinergic” or HC IgEs have not yet been determined, but the events that ensue
when such IgEs bind to the high-affinity receptor, FcεRI, on mast cells have been thor-
oughly studied, and are strikingly similar to those engendered by antigens when they form
cross-linked complexes with the receptors. We review the evidence for the cytokinergic
activity of IgE, and the structural features and known properties of immunoglobulins, and
of IgE in particular, most likely to be implicated in the phenomenon. We suggest that IgEs
with cytokinergic activity may be generated by local germinal center reactions in the target
organs of allergy.We consider also the important implications that the existence of cytokin-
ergic IgE may have for a fuller understanding of adaptive immunity and of the action of IgE
in asthma and other diseases.
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INTRODUCTION
In the classical model for allergenic activation, a multivalent
antigen – the allergen – enters the body and is captured by
a pre-existing complex of an IgE antibody bound to its high-
affinity receptor, FcεRI, on the membrane of mast cells, and
basophils. Cross-linking of the IgE-FcεRI complex triggers mast
cell activation and the release of substances that cause the symp-
toms of allergy (Figure 1A; Kinet, 1999). Allergic reactions occur
within minutes of allergen exposure, differing thereby from other
immune responses, which occur on a longer timescale. This is in
part due to the unusually high-affinity of the IgE-FcεRI interac-
tion compared to those between other antibody isotypes and their
receptors (Gould et al., 2003). Thus allergens bind to IgE-FcεRI
complexes formed on these cells in anticipation of exposure to
allergen rather than to free IgE, followed by subsequent docking
of this complex on unoccupied receptor sites. Only a minus-
cule proportion of the many receptor molecules on the mast cell
membrane need be cross-linked for “immediate hypersensitivity”
(MacGlashan, 2005). This mechanism, common to all allergic dis-
eases including allergic asthma, can take place in any bodily tissues
populated by IgE and mast cells, notably the respiratory tract, eyes,
skin, and gastrointestinal tract, or in the circulation with basophils
(systemic anaphylaxis).
Tissue targets are strategically located as barriers against the
environment, and the sensitization of mast cells to antigens by
antigen-specific IgE antibodies may be one of the many mecha-
nisms, including those of both innate and adaptive immunity that
have evolved to impede the entry of pathogens or toxins into the
body and thus avert worse mayhem than that generally caused by
mere allergic reactions (Galli et al., 1999, 2008; Palm et al., 2012).
The central dogma of allergology is that allergen cross-linking of
IgE-FcεRI complexes on the mast cells is critical for IgE-mediated
mast cell activation. The recent discovery that allergen is not
required for certain IgEs to stimulate activities resembling those
in the classical model challenges this dogma (Figure 1B). The
designation “cytokinergic” is meant to specify both the IgEs dis-
playing such activity and the type of activity itself (Kitaura et al.,
2003). The nature of allergen-independent mast cell activation by
cytokinergic IgE is unknown.
We review now the experimental evidence for cytokinergic IgE
activity and the implications for IgE functions in health and dis-
ease. Previous reviews on cytokinergic IgE have focused on the
similarities and differences in signal transduction in mast cells
by allergens and cytokinergic IgE (Kawakami and Galli, 2002;
Kawakami and Kitaura, 2005; Kashiwakura et al., 2011). Here
we consider the possible structural determinants of cytokinergic
activity in the IgE molecule itself, along with the possible origins
and biological function of cytokinergic IgE.
CYTOKINERGIC IgE ACTIVITIES
EFFECTS ON FcεRI EXPRESSION
Two types of cells, blood basophils and mucosal and connective
tissue mast cells, are responsible for the immediate hypersensitiv-
ity reactions that are the most striking characteristic of the allergic
response. Both cell types are generated in the bone marrow, but the
latter migrate to the tissues, where they differentiate into mature
mast cells expressing the high-affinity IgE receptor, FcεRI (Kita-
mura and Ito, 2005). This receptor comprises four subunits, oneα-
chain, containing the IgE binding site in its extracellular sequence,
one β-chain and two γ-chains, which are involved in synergistic
signal transduction (Kinet, 1999; Turner and Kinet, 1999). Some
35 years ago two groups discovered a positive correlation between
FcεRI levels on human basophils and the concentrations of IgE
in the serum (Conroy et al., 1977; Stallman and Aalberse, 1977).
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FIGURE 1 | Comparison between classical allergen and
cytokinergic IgE activation of mast cells. (A) In the classical
allergic response, multivalent allergens cross-link IgE-FcεRI
complexes on the surface of mast cells to trigger mast cell
activation, e.g., mast cell degranulation. (B) In contrast, the binding
of highly cytokinergic (HC) IgE to FcεRI activates mast cells in the
absence of antigen. Cytoplasmic α, and the β and γ chains of FcεRI
have been omitted for simplicity. See Figure 3 and Section
“Mechanisms of Cytokinergic Activity” for possible mechanisms for
cytokinergic IgE cross-linking of FcεRI complexes.
Several other groups later reached the same conclusion in studies
on mast cells (Furuichi et al., 1985; Hsu and MacGlashan, 1996;
Yamaguchi et al., 1997). Notably, these experiments required IgE
concentrations some 100 times higher (e.g.,>1.5µg/ml; Furuichi
et al., 1985) than those that typically suffice for allergen sen-
sitization of mast cells. In vitro experiments revealed that the
up-regulation of FcεRI is due to the inhibition of endocytosis and
under certain circumstances also de novo protein synthesis (Yam-
aguchi et al., 1997). Up-regulation of FcεRI by IgE enhances the
IgE-dependent functions of mouse and human mast cells (Galli
et al., 1999; MacGlashan, 2005). The effects of IgE binding to FcεRI
on a wide range of other cells – antigen-presenting cells such as
Langerhans cells, dendritic cells and monocytes, epithelial cells,
and muscle cells, all expressing a form of the receptor devoid of
the β-chain – are less well documented. That there are other facets
of the cytokinergic activity of IgE yet to be explored is suggested by
the existence of two other IgE receptors, CD23 and galectin-3 (Liu,
2005), and membrane IgE (the B cell receptor) on IgE-expressing
B cells (see Cytokinergic Activity of IgE Via FcεRI in Other Cells
or Mediated by Other IgE Receptors).
EFFECTS ON MAST CELL SURVIVAL
The incubation of mouse bone-marrow-derived cultured mast
cells (BMMC) with certain hybridoma IgEs has the striking effect
of increasing cell survival after removal of growth factors (Asai
et al., 2001; Kalesnikoff et al., 2001). Implication of IgE binding
to FcεRI in this effect was inferred because it was not stimu-
lated by IgG or in BMMC from an FcεRI−/− knockout mouse.
BMMC from mouse mutants were also used to exclude any pos-
sible cytokinergic activity mediated by alternative IgE receptors,
CD23, or galectin-3. Asai et al. (2001) demonstrated that IgE acted
by inhibiting apoptosis, rather than stimulating DNA synthesis,
while Kalesnikoff et al. (2001) observed up-regulation of Bcl-XL,
a known anti-apoptotic protein, which may account for this.
These authors noted that the threshold concentration of IgE
for stimulation of mast cell survival, as previously found for up-
regulation of FcεRI, was several orders of magnitude higher than
required for allergen sensitization (Asai et al., 2001; Kalesnikoff
et al., 2001). Asai et al. (2001) also observed that washing away the
unbound IgE after maximum up-regulation of FcεRI caused an
immediate loss of the survival effect, notwithstanding the persis-
tence of the IgE-FcεRI complexes available for antigen activation.
We will return to the implications of this observation later (see Is
Cytokinergic IgE Activity an Artifact of Adventitious IgE Aggre-
gation? and Dimensional Reduction and Orientation may Drive
Self-Association of FcεRI-Bound IgE). Further details relating
to IgE regulation of mast cell survival can be found in several
reviews (Kawakami and Galli, 2002; Kawakami and Kitaura, 2005;
Kashiwakura et al., 2011).
EFFECTS ON MAST CELL ACTIVATION
Both publications discussed in the previous section show the
results of additional assays of IgE stimulation of cytokine and
leukotriene synthesis and secretion and cell degranulation (Asai
et al., 2001; Kalesnikoff et al., 2001). Neither group detected
leukotriene or histamine release, although these activities were
seen in later studies with one of the IgEs, the DNP hapten-specific
SPE-7 IgE used by Kalesnikoff et al. (2001). Remarkably, SPE-7 IgE
alone stimulated interleukin (IL)-6, TNF-α, IL-4 and IL-13 mRNA,
and protein synthesis to a greater extent than antigen (DNP con-
jugated to human serum albumin; DNP-HSA) binding to the
receptor-bound SPE-7. There were significant differences in the
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kinetics of the response to SPE-7 IgE in the presence and absence
of antigen. For example, the IL-6 mRNA and protein expression
were delayed and then more prolonged in the absence of antigen.
This was also the case for various downstream effects of the IgEs,
including phosphorylation of the mitogen-activated kinases, ERK
1/2, p38 and JNK, and the survival-enhancing kinase, PKB. The
authors concluded that the cytokines must act in an autocrine or
paracrine manner to increase cell survival. Extrapolating to the
in vivo situation, they pointed out that the cytokines would also
act on cell populations other than mast cells to enhance allergic
(or cytokinergic) inflammation by, for example, inducing B cells
to make more IgE by a positive feedback mechanism (Figure 2).
It was not then clear why Asai et al. (2001) failed to observe
cytokine secretion or stimulation of signal transduction in their
experiments.
HETEROGENEITY OF IgEs
This discrepancy in the results was soon resolved by comparing the
IgEs used in these experiments (Kitaura et al., 2003). Of the eight
different hybridoma IgEs examined by Kalesnikoff et al. (2001),
three (including SPE-7 IgE) were found to be more “potent” (i.e.,
cytokinergic) than the other five. In a later survey of several DNP-
specific monoclonal IgEs, namely H1 DNP-ε-206, H1 DNP-ε-26
(Liu et al., 1980), and SPE-7 (Eshhar et al., 1980), three commer-
cially available TNP-specific IgEs, IgE-3, C48-2 and C38-2, and
an anti-dansyl IgE, 27–34, Kitaura et al. (2003) observed a wide
spectrum of effects on mast cell survival and activation. They
reproduced their earlier results with the anti-DNP H1 DNP-ε-
206 IgE (Asai et al., 2001), which again failed to stimulate cytokine
production, and the results of Kalesnikoff et al. (2001) with SPE-7,
which not only stimulated IL-6 production, but also led to syn-
thesis/secretion of leukotrienes, histamine release, internalization
of IgE, and DNA synthesis. They ranked the IgEs from highly
(HC) to poorly cytokinergic (PC) in the order SPE-7>H1 DNP-
ε-26>H1 DNP-ε-206, according to their various activities and
threshold concentrations for these activities. The activity of SPE-
7 IgE in stimulating histamine release from BMMC approached
that of the same IgE at much lower optimal concentrations, nor
was it further increased by the antigen. By contrast, the activity of
FIGURE 2 | A positive feedback loop. Mast cell activation by cytokinergic
IgE induces cytokine secretion by mast cells in the absence of antigen. The
cytokines stimulate mast cell survival and class switching to IgE in B cells.
Continued production of IgE and cytokines occurs in the absence of
antigen.
H1 DNP-ε-206 was comparably stimulated only by antigen. When
SPE-7 or H1 DNP-ε-206 IgEs were incubated in media containing
varying proportions of wild type BMMC and the FcεRI-deficient
FcεRI−/− mutant BMMC, only SPE-7 IgE provoked the wild type
cells to secrete cytokines that rescued the FcεRI-deficient cells from
apoptosis. Neutralization of IL-3, but not stem cell factor (SCF),
ablated this activity in accordance with the later demonstration of
IL-3’s importance for mast cell survival in the absence of antigen
(Kohno et al., 2005). The differential potency of the IgEs extended
to the relevant signaling cascades. Thus, SPE-7 IgE, but not H1
DNP-ε-206 IgE triggers tyrosine phosphorylation and activation
of ERK1, ERK2, p38, and Akt (Kitaura et al., 2003). Mice defi-
cient in the kinases implicated in antigen-IgE signal transduction,
namely Syk, Btk, and Lyn, were investigated. It transpired that only
Syk was required for the stimulation of survival and cytokine syn-
thesis/secretion by cytokinergic IgEs, whereas the full range of HC
IgE activities needed the signaling action of the additional kinases.
The same authors tested the effect of injecting IgE- and IgG2b-
expressing hybridoma cells into mice on the accumulation of mast
cells in different bodily locations. The greater accumulation of
mast cells in the gastrointestinal tracts of mice injected with H1
DNP-ε-26, rather than with H1 DNP-ε-206 IgE or with the IgG2b-
secreting hybridoma cells, confirmed the pro-inflammatory activ-
ity of HC vs. PC IgE in vivo, though without definitive information
on the mechanism (see Mechanisms of Cytokinergic Activity).
HUMAN CYTOKINERGIC IgE
The potential implications of cytokinergic IgE for human health
and disease prompted the investigation of cytokinergic IgE activ-
ity in human mast cells. The first indications came from Gilchrest
et al. (2003), who showed that a myeloma IgE alone stimulated
I-309 (CCL-1) mRNA expression and release of I-309 protein
from human cord blood-derived mast cells (CBMC) cultured
with growth factors, but deprived of these before the assay. I-309
(CCL-1) is the ligand for the CCR8 receptor and is responsible
for chemoattraction of T helper 2 (Th2)-type T cells, associated
with allergic inflammation. The IgE also induced the secretion
of GM-CSF and MIP-1α. These results suggest that human IgE,
through the production and release of cytokines such as I-309,
GM-CSF, and MIP-1α, could promote an inflammatory reaction in
the absence of antigen stimulation of the mast cells. Next, Matsuda
et al. (2005) showed that a myeloma IgE from the same commer-
cial source as Gilchrest’s induced secretion of IL-8 and monocyte
chemoattractant protein 1 (MCP-1) from CBMC. It was found in
both studies that addition of IL-4 to the standard culture medium
at a late stage before withdrawal of growth factors led to a more
robust response (Gilchrest et al., 2003; Matsuda et al., 2005). This
can be understood in terms of the effects of IL-4 and IgE on mast
cell differentiation and up-regulation of FcεRI (Yamaguchi et al.,
1999; Lorentz et al., 2005).
More dramatically, Cruse et al. (2005) showed that a myeloma
IgE from a different commercial source than Gilchrest’s and Mat-
suda’s, stimulated human lung-derived cultured mast cell (HLMC)
survival, IL-8 and leukotriene synthesis/secretion, and histamine
release and associated Ca2+ influx and thus could be described as
a human HC IgE. To determine whether this was a consequence
of the type of IgE (cf. murine H1 DNP-ε-206 vs. SPE-7 IgE) or
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the use of HLMC in place of CBMC would require comparison
of the different IgEs in the two types of mast cells. The same
group later demonstrated that the cytokinergic activity of their
IgE depended on the autocrine activity of IL-6 (Cruse et al., 2008),
a well-known survival factor for CBMC and LMC (Yanagida et al.,
1995; Oskeritzian et al., 2004). Thus, it is clear that certain human
IgEs are indeed cytokinergic. Later studies demonstrated that poly-
clonal human IgEs from atopic dermatitis (AD) patients also exert
cytokinergic activities (see Effects of Polyclonal IgEs).
EFFECTS ON MAST CELL MOTILITY, MIGRATION, AND ADHESION
Strikingly, studies of allergy in the mouse model have shown that
mast cells can be attracted to HC IgEs in vitro and in vivo (Kitaura
et al., 2005). This was based on a comparison of three IgEs, the
“typical” HC SPE-7 IgE and PC IgEs H1 DNP-ε-206 and IgE-E3
in an in vitro transwell migration assay. In this technique cells
placed in the upper well migrate toward IgE in the lower well.
In the case of SPE-7 IgE migration was a function of IgE con-
centration (between 1 and 30µg/ml). With H1 DNP-ε-206 and
IgE-E3 by contrast, the cells failed to migrate. The kinetics of the
migration of the cells toward SPE-7 IgE were similar to those
of IgE-sensitized BMMC migrating toward DNP-HSA. This did
not occur when BMMC from FcεRIα−/− mice were placed in the
upper well. In marked contrast, BMMC from the FcεRIα−/− mice
responded vigorously to SCF in control experiments. Wild type
BMMC pre-sensitized with PC IgEs also migrated toward DNP-
HSA. Migration of BMMC toward the HC IgE was specific to both
IgE isotype and antigen. It was necessary to coat the filter between
the wells with fibronectin, vitronectin, or laminin, but not by coat-
ing with collagen and bovine serum albumin (BSA). Migration
was inhibited in the presence of a blocking antibody against inte-
grin β1 (Kitaura et al., 2005). These effects are consistent with the
observations on HC IgE induced adhesion and spreading of mouse
mast cells on fibronectin-coated plates (Kitaura et al., 2005), and
for calcium signaling, actin assembly, and membrane ruffling and
spreading of cells of the rat basophilic leukemia cell line (Oka et al.,
2004; Pandey et al., 2004).
The corresponding in vivo experiments were conducted by epi-
cutaneous application of the same HC and PC IgEs. Skin samples
from the mice were stained for mast cells with total and degranu-
lating mast cell numbers counted. The accumulation of mast cells
was greater in the mice treated with SPE-7 IgE than with H1 DNP-
ε-206 IgE, and similar to the numbers resulting from application
of antigen to the same site 24 h after that of H1 DNP-ε-206 IgE.
EFFECTS OF POLYCLONAL IgEs
Experiments with different monoclonal IgEs were central to the
discovery of cytokinergic activity. Yet the conditions differed from
those in which mast cells encounter polyclonal IgEs in the phys-
iological state. To simulate this situation Kitaura et al. (2003)
performed experiments with a mixture of HC and PC monoclonal
antibodies, which showed that their cytokinergic activity was sim-
ply the average of their individual contributions. To develop a
more physiological assay for polyclonal IgE, Kashiwakura et al.
(2009) injected mice with a mixture of the house dust mite anti-
gen (Der f) and S. aureus enterotoxin B (a T cell superantigen)
to stimulate a vigorous IgE response, an approach designed to
provide a model of AD (Kawakami et al., 2007). Sera from the AD
mice, containing ca. 50µg/ml of IgE, and from wild type controls
containing <0.5µg/ml IgE were added at 10% of total volume to
BMMC, and the survival of the cells and cytokine secretion were
assayed. Only the AD sera stimulated both survival of the cells and
IL-6 and IL-13 secretion. Depletion of IgE from the sera reduced
the effects on survival and cytokine secretion; the effects of IgE
were not observed with BMMC from FcεRI−/− mice. Using a dif-
ferent model of AD, in which wild type and IgE−/− mice were
sensitized by epicutaneous injection of ovalbumin, the authors
confirmed that polyclonal IgE promotes mast cell survival and
cytokine secretion.
To translate these findings into a human system, Kashiwakura
et al. (2009) incubated human CBMC with a 10% v/v dilution
of serum from AD patients containing 0.5–12µg/ml of IgE, or of
serum from healthy controls, and measured the secretion of IL-
8. The AD sera were significantly more active than non-AD sera
and depletion of IgE from AD sera reduced the stimulation of
IL-8 secretion to the level attained in non-AD sera. If the poly-
clonal IgE from the AD patients were a mixture of HC and PC
IgE, this would account for the relatively small effects observed
in these experiments. However, the concentrations in skin may be
sufficient to cause or exacerbate the symptoms of AD.
DIVERGENT PATHWAYS OF SIGNAL TRANSDUCTION
Kalesnikoff et al. (2001) were the first to point out the difference
in the kinetics of mast cell activation by IgE in the presence and
absence of antigen (see Effects on Mast Cell Activation). While
antigen-triggered mast cell activation is stronger it is of short
duration, peaking in minutes, and complete within an hour. By
comparison, the activation of mast cells by cytokinergic IgE is
delayed and sustained for several hours (Kalesnikoff et al., 2001).
It was surmised that the prolonged time course reflected the
slow, asynchronous binding of IgE and assembly of the complexes
into lipid rafts within the cell membrane. Disruption of the rafts
instantly terminated signal transduction. Prolonged stimulation
by IgE alone may be required for the de novo generation of IL-3
and the survival of mast cells, but weak signaling may fail to drive
mast cell degranulation. Simultaneous binding and clustering of
the IgE-FcεRI complexes by multivalent allergens may pass the
threshold of stimulation required to induce cell degranulation;
then the signaling would be rapidly terminated by internalization
of the complexes.
Later studies confirmed these observations, clarified the points
at which the signaling pathways diverge and identified the result-
ing downstream events (Charles et al., 2004; Kitaura et al., 2004;
Pandey et al., 2004; Sakurai et al., 2004;Yamasaki et al., 2004, 2007;
Kohno et al., 2005; Nunomura et al., 2005; Sly et al., 2008). Sly et al.
(2008) propose that the weak but sustained ERK phosphorylation
in the pro-survival pathway triggers a more prolonged Ca2+ influx,
associated with the generation of reactive oxygen species (ROS)
required for induction of IL-3 synthesis. This is not seen with
antigen-dependent stimulation of mast cells. Inhibition of ROS
generation with pharmacological inhibitors, e.g., the phospholi-
pase C inhibitor U73122, converts slow to fast kinetics, while the
addition of H2O2 results in IL-3 expression and increased survival
of mast cells.
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Sly et al. (2008) suggest that local IgE synthesis, regardless of
specificity, promotes mast cell survival in mucosal tissues in a pos-
itive feedback mechanism (Figure 2). Interestingly, IgE is required
to maintain contact sensitivity, although antigen binding to IgE is
not involved (Bryce et al., 2004). These authors showed that IgE
was not required for the homing of mast cells to mucosal tissues,
but was required for the up-regulation of FcεRI on the resident
mast cells. Accordingly, the mutual dependence of IgE and FcεRI
may represent a homeostatic mechanism in immune defense, asso-
ciated with the risk of developing allergic disease. Investigations
on the signaling pathways of cytokinergic IgE are converging with
those on environmental pollution concerned with the effects of
oxidative stress in the exacerbation of asthma (Swindle and Met-
calfe, 2007; Swindle et al., 2007; Chung and Marwick, 2010; Peden,
2011). Knowledge of the mechanisms involved in the generation of
ROS by cytokinergic IgE may contribute to the rational design of
future strategies to diminish the impact of pollution (see Germinal
Center Reactions and the Local B Cell Repertoire).
MECHANISMS OF CYTOKINERGIC ACTIVITY
Is CYTOKINERGIC IgE ACTIVITY AN ARTIFACT OF ADVENTITIOUS IgE
AGGREGATION?
We consider first the possibility that has been raised of a trivial
explanation for the cytokinergic activity of IgE, based on an adven-
titious aggregation process. Such a mechanism would imply an
intrinsic propensity of IgE to aggregate in solution. Mast cell acti-
vation can be nucleated by bringing just two molecules into close
proximity and then amplified by more extensive cross-linking to
form larger clusters (Segal et al., 1977; Fewtrell and Metzger, 1980;
Field et al., 1997). The notion that IgE must be cross-linked by
antigen to initiate a signal in mast cells is so firmly entrenched
as to lead to a common suspicion that pre-existing aggregates in
the IgE preparations must be responsible for cytokinergic activ-
ity. That this is not so was painstakingly established by HPLC
purification of monomeric IgE in essentially all of the studies. It
was further shown that purified aggregates have no activity and
that their reconstitution with the monomeric IgE fraction does
not increase IgE activity (Kalesnikoff et al., 2001). Neither does
prolonged storage or pre-incubation of the IgEs with the BMMC
affect their activity. Neither is reversal of the cytokinergic activity
by specific monovalent hapten binding (Asai et al., 2001; Pandey
et al., 2004) compatible with adventitious IgE aggregation.
NATURE OF THE “ACTIVE SITES” IN CYTOKINERGIC IgE
Clustering of HC IgE in the mast cell membrane and signaling
through FcεRI implies that complexes with receptor encounter
each other directly or indirectly through one or more other mole-
cule(s). How does this occur? The available evidence points to the
involvement of contact sites in the N-terminal (Fv) domains of IgE
when it is bound to FcεRI on the mast cells. The fact that mono-
clonal IgEs with different variable regions, regardless of specificity,
linked to the same (ε) constant region, exhibited varying degrees
of cytokinergic activity implicates this domain. One caveat is that
differential glycosylation of PC and HC IgE may vary the expo-
sure of a potential “active site” in the Fc region of IgE. A key role
for the Fv domain is also supported by the observation that spe-
cific monovalent haptens inhibit the cytokinergic activity, as noted
above. The hapten may simply occupy the “active site” or binding
may stabilize an alternative conformation of the domain in which
the site is occluded or deformed. We enlarge upon the latter possi-
bility below and in Sections “Conformational Isomerism of SPE-7
IgE Facilitates Binding to Structurally Unrelated Antigens” and
“Conformational Isomerism as a Basis of Cytokinergic Allergy?”
The rank order of cytokinergic activities of different IgEs was
preserved in BMMC tested in serum-free medium (Kitaura et al.,
2003). Even in the earlier work of Kalesnikoff et al. (2001) the
medium was supplemented solely with BSA and IgE. Thus no
extrinsic proteins (other than BSA in some experiments) were
present in these systems. The reversal of cytokinergic activity when
the unbound IgE is removed from the medium may favor a model
in which the free IgE acts as a bridge between two bound IgE
molecules (Figure 3B). The participation of both Fv domains of
the bound IgE is implied by the necessity to form clusters con-
taining more than two IgE-FcεRI complexes. The rank order of
cytokinergic activities may reflect the strength of the IgE-IgE (or
IgE-X-IgE) interactions, which is likely to be determined by the
highly diverse antigen binding sites in different HC IgEs. The
inference is that cytokinergic activity may arise from conforma-
tional lability of the Fv domains, allowing exposure of “active sites”.
Hapten binding would then stabilize the preferred conformation,
resulting in the observed loss of cytokinergic activity. The nature
of the interactions has so far proved elusive.
To gain further insight into the structural requirements for
cytokinergic activity we constructed recombinant human IgEs
with different combinations of Vε and VL sequences. Vε and κ
or λVL cDNA sequences cloned from the nasal mucosa of allergic
rhinitis patients (Coker et al., 2003) were used for this purpose.
The cytokinergic activities of IgEs with random combinations of
Vε and VL were tested in either human peripheral blood-derived
cultured mast cells (PBMC; Gould et al., preliminary results)
FIGURE 3 | Alternative schematic mechanisms resulting in cytokinergic
cross-linking of IgE-FcεRI complexes. Complexes are cross-linked (A) by
receptor-bound IgE Fabs contacting regions of neighboring IgE-FcεRI
complexes or (B) by bridging with free IgE or (C) bridging by other proteins
such as HRF or autoantigens. Free IgE and HRF dimer or multivalent
autoantigen are shown in yellow.
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or in CBMC (Kawakami, personal communication) by assaying
β-hexosaminidase release (degranulation) and/or IL-8 cytokine
secretion. Independent experiments in the two laboratories led
to the same conclusion. Thus, a given VL combined with one Vε
was highly cytokinergic, while in combination with a different
Vε it exhibited only vestigial activity. Likewise, the cytokinergic
activity was not consistently associated with the presence of a par-
ticular Vε sequence. About one-third of all the recombinant IgEs
exhibited a range of activities up to the level observed with mouse
SPE-7. These results suggest that the conformation of the whole
Fv domain may be important in determining the cytokinergic
activity of an IgE; further experiments comparing the cytokiner-
gic activities of recombinant IgEs with natural and scrambled Vε
and VL pairs are in progress to resolve this question. In the follow-
ing sections we review what is known about the conformational
properties of antibody Fv regions and how they may impact on
cytokinergic activity.
CONFORMATIONAL ISOMERISM OF SPE-7 IgE FACILITATES BINDING TO
STRUCTURALLY UNRELATED ANTIGENS
Antibodies are generated by the adaptive immune system to bind
to a seemingly unlimited range of antigens. The initial response
occurs through an interaction with a pre-existing polyclonal pop-
ulation of IgM-expressing B cells. The diversity of potential bind-
ing specificities is generated by the quasi-random combinator-
ial recombination of the V, DH, and J gene segments encoding
the variable regions of the Ig heavy- and light-chains. There
is an accompanying contribution to diversity by non-templated
nucleotide insertions and deletions at the DH-JH junction. How-
ever, in practice, the comparatively low number of the body’s
circulating primary germline-repertoire B cells (ca. 106) limits this
genetic diversity. The extra diversity required for recognition of a
wider range of potential antigens originates, it has been suggested,
comes from conformational flexibility of the complementarity-
determining region (CDR) loops (Stevens et al., 1988; James
and Tawfik, 2003a; Thielges et al., 2008). Historically, structural
evidence for this conformational diversity within a germline anti-
body was inferred indirectly from comparisons of the bound and
free germline, and affinity-matured, hapten-specific antibodies
(Wedemayer et al., 1997; Yin et al., 2003). Recently, Salunke and
co-workers have directly shown that germline antibodies can
adopt multiple conformations (Khan and Salunke, 2012), with
additional diversity conferred by polyreactivity of individual con-
formers (James and Tawfik, 2003a,b; Sethi et al., 2006). Direct
evidence came from kinetic analysis of hapten binding to affinity-
matured antibodies (Lancet and Pecht, 1976; Foote and Milstein,
1994; James et al., 2003; Figure 4).
Affinity maturation leads to antibodies that bind to their anti-
gen with higher affinity and thus specificity than their germline
precursors. This can arise directly through selection of more
favorable side chains for antigen binding or indirectly by restrict-
ing the conformational flexibility of the CDR loops so as to
favor the conformation that the antibody must adopt in its
complex with the cognate antigen (Zimmermann et al., 2006,
2010; Thorpe and Brooks, 2007). Indeed, more than 90% of the
affinity-matured antibodies studied by Foote and Milstein asso-
ciate through a single-step mechanism. The pre-rigidification in
such a “lock-and-key” mechanism (Figure 5) improves binding
by reducing the entropic penalty of freezing out flexible loops
(Manivel et al., 2000) and accelerating the association rate constant
(Foote and Milstein, 1991). Conformational repositioning can also
occur upon antigen binding (Rini et al., 1992) as a result of an
“induced-fit” mechanism, whereby an initial low-affinity bimol-
ecular complex forms, which only then undergoes a rearrange-
ment to yield the final high-affinity complex (Figure 5). These
changes in the structural dynamics also act to increase antibody
specificity.
Even though SPE-7 IgE is a DNP-specific antibody of high-
affinity (K d= 2× 10−8 M, James et al., 2003), stopped-flow
kinetic experiments revealed that the antigen-free state comprises
at least, two conformational isomers. Complementary structural
studies showed that the preponderant form, Ab1 (making up some
80% of the SPE-7 molecules) has a broad and flat conformation
that resembles the state in antibody-protein complexes. By con-
trast, the minor constituent, Ab2 (ca. 20% of SPE-7 molecules) has
a deep and narrow conformation, reminiscent of antibody-hapten
complexes (James et al., 2003; Raghunathan et al., 2012; Figures 4
and 5). The presence of the two conformers enables SPE-7 to bind
FIGURE 4 | Conformational changes in SPE-7 alter the shape of the
protein surface. Antigen-free SPE-7 is in equilibrium between two
conformers – Ab1 (pdb: 1OAQ) that binds proteins and Ab2 (pdb: 1OCW)
that binds haptens (James et al., 2003). While Ab1 has a broad and shallow
surface around the key CDRH3 pocket (dashed circle), the pocket is deep,
and narrow for Ab2. After hapten binding to Ab2 a further, induced-fit
conformational change occurs resulting in the Ab3-hapten bound
conformer (pdb: 1OAU).
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FIGURE 5 | Mechanism of protein-ligand binding reactions. An
important distinction between the conformational isomerism and
induced-fit mechanisms is the step in the binding mechanism at which the
conformational change in the protein occurs – before the initial contact with
ligand in the case of conformational isomerism, but afterward in the case of
the induced-fit mechanism. The functional impact of this difference is that
conformational isomerism can drive polyreactivity by providing alternative
protein conformers for the binding of different antigens.
two types of completely unrelated antigens. Conformer Ab2 binds
promiscuously to a variety of aromatic ring compounds, with a
range of affinities between 20 nM and 100µM, while the bound
state for the more weakly binding compounds essentially resem-
bles the Ab2 conformer. Compounds of higher affinity (includ-
ing the immunizing hapten, DNP-Lys) engender an “induced-fit”
rearrangement to a third state, Ab3 (James and Tawfik, 2003b,
2005; James et al., 2003; Figure 4). Although a physiological in vivo
binding partner for the Ab1 conformer has yet to be identified, a
phage display selected thioredoxin homolog was found to bind to
it (Figure 6A), suggesting that such an interaction could occur
in vivo (James et al., 2003).
The crystal structure of the IgM rheumatoid factor, RF-AN,
bound to its autoantigen (IgG4 Fc) is instructive in this context
(Corper et al., 1997), for it shows that, rather than attaching to
conventional antibody-protein-binding CDR loop, it binds at the
edge of the loops, leaving much of the usual antigen binding site
exposed. While conformational isomerism has not been kinetically
demonstrated for RF-AN (Figure 6B), its mode of binding resem-
bles that of the SPE-7 Ab1-thioredoxin interaction (Figure 6A).
These examples complement each other as for SPE-7 the immu-
nizing antigen is known but not the true in vivo cross-reactive
protein, and vice versa for RF-AN.
CONFORMATIONAL ISOMERISM AS A BASIS OF CYTOKINERGIC
ALLERGY?
Many of the properties of SPE-7 IgE are shared with other anti-
bodies. Thus, just like the SPE-7 Ab2 conformer, many antibod-
ies show cross-reactivity against antigens with similar, though
not necessarily identical structure to that of the immunizing
antigen. This “molecular mimicry” in fact, plays an important
FIGURE 6 | Both the cytokinergic IgE SPE-7 and the autoantibody
RF-AN use similar protein surfaces to mediate cross-reactive
protein-protein interactions. (A) Crystal structure of SPE-7 IgE bound to a
phage display selected mutant thioredoxin (pdb: 1OAZ). The major SPE-7
IgE conformer (Ab1) binds to the thioredoxin to form the Ab4-thioredoxin
complex (James et al., 2003). (B) Crystal structure of the IgM autoantibody
RF-AN bound to the IgG4 Fc domain (pdb: 1ADQ; Corper et al., 1997). For
clarity only the proteins within the asymmetric unit of the crystal and the Fv
region of RF-AN are shown.
role in allergy (Valenta et al., 1991, 2009; Spitzauer et al., 1994;
Aalberse et al., 2001; Schmid-Grendelmeier et al., 2005) and
autoimmunity (Rashid and Ebringer, 2012). Moreover, other
affinity-matured antibodies have been shown by kinetic criteria
to display conformational isomerism; this pertains to as many
as 10–20% of those raised against the hapten phenyloxazolone
(Lancet and Pecht, 1976; Foote and Milstein, 1994). Further, unre-
lated antigens have been shown to bind to different conform-
ers of other antibodies (e.g., antibody D1.3 binds to lysozyme
and to the antibody E225; Bentley et al., 1990). Therefore, it
is highly unlikely that conformational isomerism is unique to
SPE-7 IgE, and may be inferred to extend to other IgEs. In
the context of cytokinergic IgE activation of mast cells, con-
formational isomerism may provide a state with the capacity
for additional protein-binding interactions. This could be to a
third protein, to free IgE, or to another self-protein, thereby
bridging two IgE-FcεRI complexes (Figures 3B,C). Alternatively,
adjacent IgE-FcεRI complexes may contact each other directly
(Figure 3A).
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A DIFFERENT KIND OF CYTOKINERGIC ACTIVITY:
HISTAMINE-RELEASING FACTOR
Heterogeneity in the cytokinergic function of IgEs immediately
brings to mind a similar phenomenon that had already puzzled
workers for over 30 years (MacDonald, 1996). Allergic individ-
uals were classified according to two groups, responders or non-
responders, depending on the ability of their serum IgE to sensitize
mast cells and basophils for the release of histamine, cytokines,
and leukotrienes by a protein present in lavage fluids obtained
from allergic lesions. IgE+ was able to sensitize basophils from
both responders and non-responders, whereas IgE− was inactive
in the absence of allergen, placing the responsibility firmly on IgE
(MacDonald et al., 1987). Histamine-releasing factor (HRF) was
purified and the gene cloned, showing its identity with a previously
known protein called translationally controlled tumor protein
(TCTP), which has a wide range of functions (MacDonald et al.,
1995). Thus the obvious candidate as HRF receptor appeared to
be IgE+ itself, but the first attempts to demonstrate direct binding
to IgE were unsuccessful (Wantke et al., 1999).
This may have been due to unfavorable experimental condi-
tions (perhaps the limited range of IgEs or the assay conditions).
Nevertheless, in early 2012 binding of recombinant mouse HRF
to certain mouse monoclonal IgE+ and IgG+ preparations and to
polyclonal mouse IgE+ was demonstrated (Kashiwakura et al.,
2012a). The use of a large panel of monoclonal Igs together
with BMMC revealed that recombinant HRF bound with varying
strength to about one-third of the Igs, and that potency of the IgEs
in assays of HRF-induced airway inflammation was roughly cor-
related with this binding activity. Injection of the HRF into mice
of different genetic deficiencies showed that the airway inflamma-
tion is dependent on mast cells, B cells, FcεRI, and the FcR γ-chain.
Monoclonal IgE+, but not IgE− induced passive cutaneous ana-
phylaxis in mice, mediated by FcεRI - a further demonstration of
in vivo activity.
The structural properties of IgE+ were investigated. Their Fabs
were as active in binding HRF as intact IgE molecules, and binding
was inhibited by antigen, implying that HRF binds at a site in the
variable regions. Interestingly, there appeared to be a relation to
the presence of κ-chains derived from two particular members of
the κ germline gene family (8–30 and 2–137), paired with heavy-
chains from different VH families. Recombinant HRF was also
split into smaller fragments, two of which inhibited HRF activities
in vitro and in vivo in mice. The activity of the corresponding HRF
peptides in the human system remains to be evaluated; clinical
applications may be envisaged.
The native HRF is a dimer with two disulfide bonds uniting the
subunits. Cysteine to alanine mutations or reduction of the disul-
fide bonds eliminated the activity in IgE+-mediated BMMC or
peritoneal mast cell activation (Kashiwakura et al., 2012a). These
authors propose a model to explain how dimeric HRF molecules
are able to cross-link IgE-FcεRI complexes to activate the mast
cell (Figure S8 in Kashiwakura et al., 2012a). The presence of two
different inhibitory sequences in HRF implies the existence of two
different contact sites in each IgE+ Fv. A simplified form of the
complex, utilizing one Fv in each of two adjacent IgE-FcεRI com-
plexes and only one of the contact sites in each subunit of the
HRF dimer is represented in Figure 3C. It is easy to envisage how
such a complex might nucleate larger clusters through the vacant
contact sites to form an effective signaling platform for mast cell
activation.
The lack of cytokinergic activity of IgE+, even at high concen-
trations, in the absence of HRF, and the lack of HRF responsiveness
of SPE-7 IgE and other HC IgEs (at low concentrations) show
that the two activities are not equivalent (Xie et al., 2008; Kashi-
wakura et al., 2012a). However, neither HC IgE nor IgE+ require
the presence of an antigen, and therefore both may be considered
as “cytokinergic IgEs” according to the original definition (Kitaura
et al., 2003).
The examples here of HC and IgE+ illustrate the potential for
multiple mechanisms of cytokinergic IgE activity. Both HC IgE
and IgE+ are evidently involved in allergic inflammation in the
absence of allergen. Both are implicated in the exacerbation of
atopic asthma and allergy. Cytokinergic IgE activity may provide a
rationale for the paradoxical observation that the risk of develop-
ing an “allergic disease” and severity of the disease is more closely
related to the levels of total IgE than allergen-specific IgE in serum
(Burrows et al., 1989; Sunyer et al., 1996; Beeh et al., 2000). It
may also account for “allergic disease” in non-atopic patients, in
whom the usual skin prick tests for allergen sensitivity and serum
titers of allergen-specific IgE are negative, but who present with
the usual signs and symptoms of allergic disease (see Germinal
Center Reactions and the Local B Cell Repertoire).
CYTOKINERGIC ACTIVITY OF IgE VIA FcεRI IN OTHER CELLS OR
MEDIATED BY OTHER IgE RECEPTORS
Cells other than mast cells and basophils express FcεRI (the “high-
affinity” IgE receptor) and many types of cells express CD23 (the
“low-affinity”IgE receptor). FcεRI is expressed in Langerhans cells,
dendritic cells, monocytes, smooth muscle cells, and epithelial
cells, while CD23 is expressed in many of these cell types and
also in B cells, T cells, and follicular dendritic cells (Gould et al.,
2003; Gould and Sutton, 2008). There are two splice variants of
human CD23, CD23a, and CD23b, differing in 6/7 amino acids
at the cytoplasmic N-terminus; these are expressed in different
circumstances and have different functions (Gould et al., 2003;
Gould and Sutton, 2008). Galectin-3, also known as Mac-1 and
IgE binding factor (Huff et al., 1983), binds to both IgE and FcεRI,
amongst other ligands (Liu, 2005). Early experiments with BMMC
from mice in which the genes were inactivated argue against a role
for CD23 or galectin-3 in mediating cytokinergic IgE activity (see
Effects on Mast Cell Survival).
A recent study suggests that macrophages may exert cytokin-
ergic IgE activity through FcεRI in an important physiological
context – atherosclerosis (Wang et al., 2011). Serum IgE levels
were elevated in two groups of Chinese patients with myocar-
dial infarction or unstable angina pectoris. IgE and FcεRI were
observed in atherosclerotic lesions and localized to the majority of
macrophages and a minority of smooth muscle cells and epithe-
lial cells in the tissue. A fat diet was used to develop a mouse
model of atherosclerosis. The disease was attenuated in FcεRI−/−
and TLR−/− mice suggesting synergistic activity between these
receptors. IgE in the range of 6–100µg/ml stimulated signal trans-
duction and cytokine secretion by isolated macrophages from the
mice and SPE-7 IgE was more potent than H1 DNP-ε-206 IgE.
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Weaker IgE responses could be induced in the smooth muscle cells
and epithelial cells. The large discrepancy in the concentration of
IgE required to activate mast cells and macrophages may reflect the
relatively low levels of receptor expression or absence of the signal
amplifier β-chain in these cells. Since there are few B cells in the
tissue, IgE must be imported from the circulation. It is certainly
questionable whether local IgE concentrations in heart tissue ever
reach the levels required for macrophage activation,although heart
mast cell involvement in cardiac disease is by now well established
(Genovese et al., 2010).
No activities of HC IgE in IgE-expressing B cells have come
to light. SPE-7 IgE hybridoma cells appear to grow normally and
IgE levels in the culture media rise well above the concentrations
required for cytokinergic activity in mast cells. High concentra-
tions of the FcεRI and the topology of HC IgE-FcεRI complexes in
the membrane of mast cells (and other FcεRI bearing cells) may
be critical for cytokinergic IgE activity (see Fab Pre-Orientation
in the IgE-FcεRI Complex on the Mast Cell Membrane). In so
far as mast cells are implicated in diseases other than allergy, e.g.,
autoimmunity, HIV infection, and malaria, cytokinergic IgE may
have a wider significance in disease pathogenesis.
SECONDARY RECEPTOR EDITING AS A SOURCE OF CYTOKINERGIC IgEs
A cost/benefit balance is implicit in the possession of a large
antibody-directed repertoire while precluding antibody target-
ing of self-antigens (Ehrlich’s horror autotoxicus; Ehrlich, 1900).
Induction of tolerance to self-antigens is inseparable from the
prevention of autoantibody formation, given that after V(DH)J
recombination in the bone marrow up to 75% of B cells are self-
reactive (Wardemann et al., 2003; Nemazee, 2006). During B cell
development within bone marrow, tolerance is achieved through
a combination of deletion of self-reactive B cells and receptor
editing. The editing involves exchange of the V-segment attached
to DJ-Cµ for the heavy-chain, or of the J-Cκ or J-Cλ for the
light-chain, thereby altering the B cell receptor specificity, so that
it no longer recognizes the self-antigen. It is now clear (Eisen-
berg, 2012) that, after release from the bone marrow, B cells that
have migrated to peripheral lymphoid tissue can undergo further
rounds of receptor editing, called “receptor revision.” On the one
hand, this may serve to eliminate self-reactive B cells that escape
from the bone marrow or are generated by somatic hypermutation
in the periphery. On the other, this process may generate polyspe-
cific, autoreactive B cells anew, either before or after switching to
IgE, that may exert cytokinergic activity. Studies on circulating B
cells have shown that a significant proportion (∼5%) produce
polyspecific IgM and IgG (Wardemann et al., 2003; Nemazee,
2006), of which a proportion may be generated in the periphery.
The sequence of events in receptor editing and revision is itself
well characterized. The Th2 inflammatory cytokine IL-6 induces
the expression of RAG1 and RAG2, products of the recombination
activating genes rag1 and rag2. A complex of RAG1 and RAG2
can itself initiate the process of receptor revision, since all the
other machinery for repairing DNA breaks in cells is constitutive
(Nemazee, 2006). RAG genes are normally silenced once a func-
tional Ig is expressed in B cells, but may be re-expressed in the
presence of IL-6 (Hillion et al., 2007a,b). IL-6 secretion is com-
monly observed when mast cells are stimulated by cytokinergic
IgE; when this occurs in the target organs of allergy, it may lead to
the local expression of polyspecific/cytokinergic IgE.
Polyspecific IgE is well characterized in at least two pathologi-
cal conditions, parasitic worm infection, and chronic sinusitis with
polyps (ChRwP). Helminths induce Th2-type immune responses
and regulatory T cells that produce anti-inflammatory cytokines.
This is accompanied by the synthesis of abundant polyspecific IgE,
little or none of which is specific for the parasite antigens (Harnett
and Harnett, 2010). This appears to be the parasite’s strategy to
evade detection and elimination by the host immune system. Sim-
ilarly, nasal polyps in ChRwP are characterized by the presence of
abundant Th2 cytokines, regulatory T cells, and polyspecific IgE.
Compelling evidence supports the hypothesis that S. aureus infec-
tion causes this polyposis, yet only small proportions of the IgE are
directed against the bacterial proteins and allergens (Zhang et al.,
2011). The high concentrations of polyspecific IgE may well exert
cytokinergic activity, contributing to chronic inflammation and
allowing S. aureus to exist in the commensal state. Re-expression
of RAG1 and RAG2 in the nasal B cells and receptor revision may
be instrumental in generating the polyspecific IgE to disarm the
immune response.
STRUCTURAL IMPACT OF SECONDARY EDITING ON Fv PROPERTIES
After affinity maturation of binding to a specific antigen, residues
from the three CDR loops on the heavy- or light-chains, and
often both, directly contact the antigen, an event in which CDRH3
often plays a dominant role (Stanfield et al., 1993). CDRH3 lies
close to the VH-VL domain interface; the relative orientation of
the domains changes on antigen binding (Stanfield et al., 1993;
Teplyakov et al., 2011), and also in the course of affinity matu-
ration, thus enhancing the affinity of antigen binding (Chatellier
et al., 1996), as discussed in Section“Conformational Isomerism of
SPE-7 IgE Facilitates Binding to Structurally Unrelated Antigens.”
The relative orientations of the VH-VL domains vary considerably;
thus one analysis of the crystal structures shows that their angular
disposition varies between −60.8˚ and −31.0˚ (Abhinandan and
Martin, 2010). Mutations at the VH-VL interface also affect the
structural stability of the Fv region (Chatellier et al., 1996; Vargas-
Madrazo and Paz-Garcia, 2003; Nakanishi et al., 2008; Caravella
et al.,2010). It appears then that after receptor revision the newVH-
VL may well be less stable than the original Fv, thus alteration of
the VH-VL pairings could increase the conformational isomerism
enabling antibodies to interact with themselves (self-association)
or other proteins (Figure 3). Mutations at particular positions in
the VH interface with VL have been used to create single chain
antibodies, similar to those expressed in camels (Barthelemy et al.,
2008). Certain VH-VL combinations may actually result in domain
swapping between IgEs bound to adjacent FcεRI on mast cells, or
between the bound and free IgEs (see below).
DIMENSIONAL REDUCTION AND ORIENTATION MAY DRIVE
SELF-ASSOCIATION OF FcεRI-BOUND IgE
The evidence so far available suggests that cytokinergic activ-
ity is related to receptor clustering on the surface of mast cells,
and that HC IgEs induce more extensive clustering than PC IgEs
(Kalesnikoff et al., 2001; Kitaura et al., 2003). This process must
depend in large measure on the enormous increase in binding
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affinity that results when the reactants are confined in the plane
of the membrane, by reason of their high concentration in two
dimensions and their much-reduced orientational freedom (see
e.g., DeLisi (1981) who calculates a reduction by a factor of about
105 M in K d relative to the same reactants in free solution). The
likelihood therefore is that, in the normally attainable concentra-
tion range, interaction between the molecules we are considering
would be undetectably low in solution. Schweitzer-Stenner and
Pecht (2005) have modeled the situation for varying numbers
of FcεRI molecules per cell. With typical numbers, e.g., 3× 105
molecules/cell, the probability of productive collisions would be
extremely high. Thus, given the mobility of receptors in the mem-
brane, the ability of IgEs to self-associate after they bind to FcεRI,
is plausible. There is moreover ample evidence for Fab-mediated
self-association of antibodies at high local concentrations; thus,
Shire and co-workers have used the anti-IgE omalizumab as a case
study for such a phenomenon (Yadav et al., 2012). This could
occur, for example, through the variable region on one Fab con-
tacting the variable or constant region on another (Figure 3A). A
range of potential orientation modes for self-association has been
observed crystallographically, with the most extreme case being
domain swapping (Boehm et al., 2000; Lee et al., 2002; Calarese
et al., 2003; Igawa et al., 2010; Figure 7).
Fab PRE-ORIENTATION IN THE IgE-FcεRI COMPLEX ON THE MAST CELL
MEMBRANE
IgE possesses unique properties that may pre-dispose it to cytokin-
ergic activity. The high-affinity of binding (K d∼ 10−10 M) and
slow dissociation (t 1/2∼ 14 days in tissue) imply that IgE is effec-
tively permanently attached to FcεRI on the cell membrane. IgE
has one more pair of Ig domains in its Fc region than IgG, which
causes IgE to adopt an asymmetrically bent structure (Wan et al.,
2002; Hunt et al., 2012). The bend becomes more acute on bind-
ing to FcεRI (Holdom et al., 2011; Hunt et al., 2012), causing
the extra (Cε2) domains to orient the Fab domains away from
the membrane, thus giving less obstructed access to the antigen
(Figure 8). We surmise that the angular freedom of the Fabs allows
the IgE to accept a wider range of antigens. Structural freedom
may, on the other hand, also promote interactions with each other
or other molecules to promote cytokinergic activity. We suggest
that this structurally predetermined orientation of the Fabs may
play an important role in predisposing the mast cells and other
cells expressing FcεRI to cytokinergic IgE activation.
Activation of mast cells in the allergic response is initiated by
antigen-induced cross-linking of cell surface IgE-FcεRI. The opti-
mum distance between the antigen epitopes was measured with
rigid bivalent allergens (DNP-modified oligodeoxynucleotides),
showing that there needs to be sufficient proximity of the cross-
linked complexes (<70 Å apart) for significant stimulation of
degranulation, although signaling upstream of the Ca2+ response
was unimpaired with greater distances between the epitopes (Paar
et al., 2002). The crystal structures of two allergens each bound
to two IgE antibody Fabs show an approximately linear structure
(Li et al., 2008), compatible with the presentation of the Fabs ori-
ented perpendicular to the membrane when IgE binds to FcεRI on
the mast cell (Niemi et al., 2007). Pre-orientation of the IgE Fabs
FIGURE 7 | Crystal structures reveal alternative modes of antibody
self-interactions. (A) VH-VL interactions are seen for the scFv of MFE-23
(pdb: 1QOK; Boehm et al., 2000). (B) VH domain swapping between the
anti-HIV Fab 2G12 (pdb: 1OM3; Calarese et al., 2003).
would also allow self-interaction or bridging, e.g., by free IgE or
HRF (Figure 3).
MOST HC IgEs HAVE POLYREACTIVITY TO AUTOANTIGENS
Human IgEs do not bind to mouse FcεRI, but mouse IgE does bind
to human FcεRI (Conrad et al., 1983). Conveniently, this allows
mouse IgEs, as well as human IgEs, to be tested for polyreactiv-
ity in human FcεRI-expressing cells. To examine the relationship
between cytokinergic IgE activity and polyreactivity Kashiwakura
et al. (2012b) tested a number of well characterized mouse and
human HC and PC IgEs for binding to a panel of autoantigens
routinely used for the diagnosis of autoimmunity (single- and
double-stranded DNA, thyroglobulin, β-galactosidase) and HRF.
They also confirmed the cytokinergic activity of two of the human
IgEs (Matsuda et al., 2005) and compared the cytokinergic activity
of sera containing polyclonal IgE from AD patients and healthy
controls in CBMC.
These experiments demonstrated that mouse HC but not PC
IgEs, and the human monoclonal IgEs that exhibited cytokiner-
gic activity in the earlier study, recognized one or more of the
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FIGURE 8 | Modeling of IgE bound to FcεRI reveals that one of the Fabs
predominately lies parallel to the membrane. Each sphere represents a
possible position of the antigen binding site of the Fab. Cε4 is present, but
obscured by Cε2 and 3. The modeled structure not only accounts for the
observed restricted mobility of Fabs on IgE relative to IgG, but also suggests
that two neighboring IgE-FcεRI complexes are pre-disposed for ready
cross-linking either by self-association or through a bridging protein. For more
details of modeling see Hunt et al. (2012).
autoantigens. Sera from AD patients but not the healthy con-
trols showed increased reactivity against the single- and double-
stranded DNA and β-galactosidase and increased levels of HRF.
Sera from AD patients with DNA-reactive IgE induced more IL-
8 secretion from CBMC than sera from healthy controls. The
individual HC IgEs bound to different subsets of these autoanti-
gens, showing that there are multiple modes of IgE-FcεRI self-
association responsible for cytokinergic IgE activity, consistent
with the heterogeneity of cytokinergic IgEs based on the strength
of signal transduction (see Heterogeneity of IgEs). This is the result
that would be expected if cytokinergic IgE activity arises from the
random association of heavy- and light-chains after VDHJ recom-
bination (cf. Wardemann et al., 2003), receptor editing, or receptor
revision and switching to IgE.
Many previous studies have revealed the existence of IgE
autoantibodies (see Conformational Isomerism as a Basis of
Cytokinergic Allergy?). Some of these are known to mediate mast
cell activation in the classical manner with autoantigens (Valenta
et al., 2009). The new insight offered by Kashiwakura et al. (2012b)
is that there may be a cytokinergic element in IgE autoimmunity.
POSSIBLE ORIGINS AND BIOLOGICAL SIGNIFICANCE OF
CYTOKINERGIC IgE ACTIVITIES
GERMINAL CENTER REACTIONS AND THE LOCAL B CELL REPERTOIRE
An alluring conjecture is that HC IgEs could be created de novo
in the target organs of inflammation, caused by allergens or alter-
natively by non-allergic mechanisms, such as viral or bacterial
infections. The resulting inflammatory cytokines may in turn
induce polyclonal B cell proliferation and lymphoid neogene-
sis; i.e., the formation of tertiary lymphoid tissue, promoting
germinal center reactions. The location of these events, deter-
mined by the cytokine environment, may specify the antibody
class by directing class switching, e.g., to IgG in the synovial
tissue in rheumatoid arthritis or IgE in the respiratory tract
mucosa in rhinitis and asthma. Lymphoid neogenesis is well
recognized in chronic autoimmune diseases, chronic infections,
and B cell malignancies (Aloisi and Pujol-Borrell, 2006). It also
occurs normally in the gastrointestinal tract, which is under con-
stant bombardment from a complex and ever-changing mixture
of bacterial products (Spencer et al., 2009). It has received less
attention in relation to allergic disease, where IgE is the rele-
vant antibody class, and to which we will confine our discus-
sion.
By germinal center reactions we mean those that cause changes
in the sequence of the expressed Ig genes in B cells secondary
to the original VDHJ recombinatorial diversity created in bone
marrow. This takes its name from the classical germinal cen-
ters located in secondary lymphoid tissue. The three germinal
center reactions in B cells are somatic hypermutation, receptor
revision, and class switch recombination. Somatic hypermuta-
tion introduces point mutations in the variable regions of the Ig
heavy- and light-chains, which may either increase or decrease
the affinity for an antigen and serves as the basis for affin-
ity maturation in the immune response. In the mechanism of
class switch recombination, the expressed variable region gene is
recombined with one of the downstream constant region genes
in the tandem array in the Ig heavy-chain locus on chromo-
some 14 and this diversifies the effector function and anatom-
ical distribution of the antibody. Receptor revision is perhaps
the most dramatic event, since it almost inevitably leads the B
cell to lose its original antigen specificity or at least its affin-
ity, but also offers a small chance of acquiring a new specificity
against an environmental antigen. We suggest that randomization
of the heavy- and light-chain combination in IgE is the origin of
cytokinergic IgE (see Secondary Receptor Editing as a Source of
Cytokinergic IgEs).
www.frontiersin.org August 2012 | Volume 3 | Article 229 | 11
Bax et al. Mechanisms of cytokinergic IgE activity
There is ample evidence for the induction of tertiary lymphoid
tissue and germinal center reactions in the respiratory tract in
allergic disease. Local somatic hypermutation is revealed by the
presence of clonal families in the nasal mucosa in rhinitis (Coker
et al., 2003, 2005) and in the bronchial mucosa in asthma (Snow
et al., 1995, 1997, 1998). Receptor revision is supported by the
presence of RAG1 and RAG2 proteins in the tissue and the altered
B cell repertoire (Coker et al., 2005). The abundance of Th2 and
mast cells secreting IL-4, IL-13, and IL-6 provides an ideal environ-
ment for receptor revision and local class switching to IgE. Class
switch recombination to IgE is experimentally observed by the
presence of activation-induced cytidine deaminase in the tissue,
along with ε germline gene transcripts, ε switch circle transcripts,
ε-chain mRNA, and members of the same clonal family in IgE
and IgA (Cameron et al., 2003; Coker et al., 2003;Takhar et al.,
2005, 2007; Gould et al., 2006). The observed outcome is a mas-
sive increase in the proportion of IgE-expressing B cells (1/24), and
of the plasma cells (1/8) in the nasal mucosa in rhinitis, compared
to 1/10,000 of IgE-expressing B cells in the circulation (KleinJan
et al., 2000). In atopic rhinitis allergen-specific IgE produced by
B cells in the nasal mucosa forms a substantial minority of the
total RNA, and invariably a greater proportion than it represents
in the circulation (Smurthwaite et al., 2001). We have estimated
that the rate of IgE antibody synthesis in the nasal mucosa is 100
times greater than that required to saturate FcεRI on mast cells
in the tissue (Gould et al., 2003). Therefore the local IgE con-
centrations must be sufficient for cytokinergic activity. IgE in the
circulation may simply be the spill over from respiratory tract and
other tissue compartments (Gould et al., 2006; Eckl-Dorna et al.,
2012).
Germinal center reactions are transient in secondary lymphoid
tissue because they feed on the antigens that are eliminated in the
immune response. Yet one cannot exclude the possibility that the
target organs of allergic disease provide a survival niche for IgE-
expressing B cells and plasma cells (Luger et al., 2009). In principle,
this could be due in part to the cooperation between the B cells
that continue to secrete IgE that binds to neighboring mast cells
that respond to the IgE, according to the positive feedback mech-
anism illustrated in Figure 2. Persistent production of HC IgEs in
the tissue may thus lead to the symptoms of chronic disease in the
absence of allergen. Preliminary evidence showing the activity of
cytokinergic IgEs produced by the randomization of ε heavy- and
light-chains in recombinant IgEs derived from the nasal mucosa
of rhinitis patients (see Nature of the “Active Sites” in Cytokinergic
IgE) is fully consistent with this scenario.
In summary we suggest the following pathway via cytokinergic
IgE to chronic disease:
Primary (viral, bacterial, allergic) inflammation in the target
organs of allergy→ somatic hypermutation, receptor revision,
and class switching to IgE→ IgEs with instability in Fv due to
random combination of VH and VL sequences during receptor
revision→ polyspecific cytokinergic IgE→ chronic disease.
What then might be the biological function of local receptor
revision and the production of polyspecific cytokinergic IgE in the
respiratory tract and gastrointestinal mucosa and skin? All these
are barrier tissues involved in immune defense against multitudi-
nous ever-changing external threats. It may be vital to maintain
the diversity of the local antibody repertoire (Spencer et al., 2009),
and this is surely an effective, but risky strategy.
DIAGNOSIS AND THERAPY
IgE is central to allergic disease but as we have indicated above
IgEs are heterogeneous and similar symptoms are generated by
different pathomechanisms. Cytokineric IgEs may be produced
in an inflammatory response and may cause the symptoms of
allergy in the absence of allergen. The non-anaphylactogenic anti-
IgE antibody, omalizumab, has proved to be a generally effective
therapy in the clinic for moderate to severe asthma and in a wide
variety of pre-clinical investigations on other allergic conditions.
Since omalizumab acts by competing with FcεRI for IgE bind-
ing it does not prevent IgE synthesis. Therefore, intensive efforts
have been devoted to do this. For example, IgEs have been engi-
neered to target the extra-membrane-proximal domain of IgE on
B cells to induce cell death (Feichtner et al., 2008; Brightbill et al.,
2010; Chen et al., 2010). The murine precursor of omalizumab has
been re-engineered to increase its affinity for IgE and induce the
co-ligation of membrane IgE and FcγRIIb, which inhibits IgE syn-
thesis, as well as neutralizing free IgE (Chu et al., 2012). It has been
lamented recently that both anti-IgE therapies and the more com-
monly prescribed anti-inflammatory corticosteroids have actually
been “too successful,” in that they benefit patients with different
underlying pathobiologies (Drazen, 2012). A better understand-
ing of these pathobiologies would enable more specific diagnostic
tests and targeted treatments.
We have attempted in this review to alert the reader to the
different modes of IgE activity in the activation of mast cells and
basophils. Inhibitors of oxidative stress (see Divergent Pathways of
Signal Transduction) and of HRF binding to IgE (see A Different
Kind of Cytokinergic Activity: Histamine-Releasing Factor) have
been flagged up as potential therapies to intervene in the activity
of cytokinergic IgE, but further research will undoubtedly uncover
others.
CONCLUSION AND UNANSWERED QUESTIONS
We hope we may have persuaded the reader that cytokinergic activ-
ity is no mere academic curiosity, relevant only to model hapten-
specific mouse antibodies acting on cultured mast cells, but that it
is likely also to trouble humans. Most provocative perhaps may be
the conjecture that these cytokinergic IgEs play a part in triggering
and perpetuating the symptoms of allergic rhinitis and asthma.
Therefore, this seems to us an area of no small topical interest.
If it be granted that cytokinergic activity is a real immunologi-
cal phenomenon, then the immediate challenges in understanding
its molecular basis are mainly structural, biochemical, and bio-
physical. The conjectural mechanisms we have outlined of the
events that follow the binding of a cytokinergic IgE to the mast
cell need to be tested. Detailed structural and dynamic studies
have so far been confined to a single case (SPE-7 IgE), and need
to be extended to other cytokinergic IgEs to establish the general-
ity of the conclusions. Nor has anything yet been undertaken to
relate the highly variable level of cytokinergic activity to amino
acid sequence differences. Additional questions also arise: are dif-
ferences in cytokinergic IgE potency linked to degree of conforma-
tional mutability? Are the structural and dynamic characteristics
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of the IgEs governed to any significant extent by the VH and VL
pairings? Are the VH and VL sequences and pairings in IgE in the
target organs of allergy unique to these sites, inasmuch as they
are probably generated de novo by local germinal center reactions?
What is the evolutionary advantage of cytokinergic IgEs? Consid-
ering their apparent place in the front-line of immune defense, do
they perhaps perform an innate immune function, rather like the
circulating IgM produced by naïve B cells? Do cytokinergic IgEs
also pose a risk of engendering a “pseudo-allergy” and, if so, how
might one intervene to promote or suppress their formation? The
answers to many of these questions are well within the reach of
present-day technology.
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